Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | CCR2 | P41597 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340280 | 0.89 | CCKBR (0.46) | CCKBRSCN9ACCR2CYP2D6CYP2C9 | |
| SCHEMBL6334392 | 0.84 | CCKBR (0.42) | CCKBR | |
| SCHEMBL6158023 | 0.82 | CCKBR (0.66) | CCKBRSCN9ACCR2CYP2D6CYP2C9 | |
| SCHEMBL6330927 | 0.76 | CCKBR (0.59) | CCKBRSCN9ACCR2 | |
| SCHEMBL6330221 | 0.74 | CCKBR (0.65) | CCKBRSCN9ACCR2CYP2D6CYP2C9 | |
| SCHEMBL7998857 | 0.73 | CCKBR (0.37) | CCKBRCCR2CYP2D6CYP2C9 | |
| SCHEMBL6096321 | 0.71 | CCKBR (0.61) | CCKBR | |
| SCHEMBL6332407 | 0.71 | CCKBR (0.47) | CCKBR | |
| SCHEMBL6159765 | 0.71 | CCKBR (0.56) | CCKBRSCN9ACYP2D6CYP2C9CYP1A2 | |
| SCHEMBL6160427 | 0.70 | CCKBR (0.69) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878734-B2 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | CCKBR 2/4885SCN9A 2377/4885CCR2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.